S96 South West experience of continuous positive airway pressure non-invasive ventilation for COVID-19

IntroductionContinuous positive airway pressure non-invasive ventilation (CPAP) was recommended by NHS England for patients with COVID-19 and hypoxaemic respiratory failure either as a ceiling of treatment, trial to avoid intubation or as a bridge to intubation.1 However, In the absence of clinical trials, its role in the treatment of COVID-19 is poorly understood. We collected observational data on outcomes of patients with COVID-19 requiring CPAP.MethodsData was collected by members of the PRISM trainee research network. Patient demographics, comorbidities, Rockwood clinical frailty scale (CFS) and outcomes (death or discharge) were collected for patients requiring CPAP for hypoxaemic respiratory failure with confirmed or clinically suspected COVID-19 across 6 sites in the South West over 11 weeks from March – June 2020.ResultsData was collected for 164 patients. Ages of patients ranged from 30 – 88 years (mean 62.13), 110 (61.1%) male. Most patients received CPAP on a respiratory ward (79.3%).A treatment escalation plan was recorded for 153 (85%) of patients on admission to hospital. Of 100 patients eligible for escalation to intensive care (ICU), 50 required intubation and invasive mechanical ventilation (IMV) despite CPAP therapy.CFS scores ranged from 1 to 7 (mean 2.5). Average CFS score those eligible for IMV was 1.75, compared to 3.67 for those who were deemed ineligible for IMV. Mortality data are shown in table 1. Average length of stay for survivors was 15.6 days (1 – 63). The average number of days from admission to death was 8.6 (0 – 48).Abstract S96 Table 1Mortality of different patient groups. *p